We focus on

Mar 30 2021

SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines

SERB Specialty Pharmaceuticals (“SERB”), a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases, today announced the acquisition of BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops, manufactures, and commercializes antidotes and rescue medicines to treat patients with critical conditions.